
A brand new FDA approval means Medilink can launch Hydrozid on the world's largest markets for pharmaceutical and medtech products.
"Since 2015, we've experienced tremendous growth, as providers have experienced how easy and convenient Hydrozid is to use, and most importantly, how effective it is in treating warts and other skin conditions," said Christian Kjerulf-Jensen, CEO of Medilink, in a press release.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app